Core Insights - MacroGenics reported a revenue of $10.8 million for Q2 2024, marking a year-over-year decline of 17.8% and an EPS of -$0.89 compared to -$0.36 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $24.14 million, resulting in a surprise of -55.28%, while the EPS surprise was -89.36% against a consensus estimate of -$0.47 [1] Revenue Breakdown - Product sales generated $5.25 million, slightly below the average estimate of $5.73 million, reflecting a year-over-year increase of 3.7% [3] - Revenue from government agreements was $0.49 million, exceeding the estimated $0.45 million, representing a year-over-year increase of 5.8% [4] - Revenue from collaborative and other agreements was $2.07 million, significantly lower than the average estimate of $8.61 million, indicating a year-over-year decline of 65.7% [5] Stock Performance - Over the past month, MacroGenics shares have returned -15.4%, compared to a -6.7% change in the Zacks S&P 500 composite [5] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [5]

MacroGenics (MGNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.36 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -89.36%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.67 per share when it actually produced a loss of $0.84, delivering a surprise of -25.37%. Over the last four quarters, the com ...

NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MacroGenics investors who were adversely affected by alleged securities fraud between March 7, 2024 and May 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submi ...

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of MacroGenics, Inc. (NASDAQ: MGNX) stock or sellers of MacroGenics puts between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), have until September 24, 2024 to seek appointment as lead plaintiff of the MacroGenics class action lawsuit. Captioned Crain v. MacroGenics, Inc., No. 24-cv-02184 (D. Md.), the MacroGenics class action lawsuit charges MacroGenics as well ...

NEW YORK, Aug. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=93533&from=4 CLASS PERIOD: March 7, 2024 t ...

SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX). If you incurred significant losses and want to act as the lead plaintiff in the MacroGenics class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: SUBMIT YOUR INFORMATION NOW CLASS PERIOD: March 7, 2024 to May 9 ...

NEW YORK, Aug. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MacroGenics investors who were adversely affected by alleged securities fraud between March 7, 2024 and May 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submi ...

NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2024. To join the MacroGenics class action, go to https://rosenleg ...

RADNOR, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period") The lead plaintiff deadline is September 24, 2024. CONTA ...

NEW ORLEANS, July 31, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 24, 2024 to file lead plaintiff applications in a securities class action lawsuit against MacroGenics, Inc. (or the "Company") (NasdaqGS: MGNX), if they purchased the Company's shares or sold the Company's puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Mar ...